Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incorporating Supramaximal Resection into Survival Stratification of IDH-wildtype Glioblastoma: A Refined Multi-institutional Recursive Partitioning Analysis.
Park YW, Choi KS, Foltyn-Dumitru M, Brugnara G, Banan R, Kim S, Han K, Park JE, Kessler T, Bendszus M, Krieg S, Wick W, Sahm F, Choi SH, Kim HS, Chang JH, Kim SH, Wongsawaeng D, Pollock JM, Lee SK, Barajas RF Jr, Vollmuth P, Ahn SS. Park YW, et al. Among authors: kessler t. Clin Cancer Res. 2024 Nov 1;30(21):4866-4875. doi: 10.1158/1078-0432.CCR-23-3845. Clin Cancer Res. 2024. PMID: 38829906
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T, Sahm F, Blaes J, Osswald M, Rübmann P, Milford D, Urban S, Jestaedt L, Heiland S, Bendszus M, Hertenstein A, Pfenning PN, Ruiz de Almodóvar C, Wick A, Winkler F, von Deimling A, Platten M, Wick W, Weiler M. Kessler T, et al. Oncotarget. 2015 Oct 13;6(31):31050-68. doi: 10.18632/oncotarget.2910. Oncotarget. 2015. PMID: 25682871 Free PMC article.
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W. Kessler T, et al. Neuro Oncol. 2018 Feb 19;20(3):367-379. doi: 10.1093/neuonc/nox160. Neuro Oncol. 2018. PMID: 29016808 Free PMC article.
Drug Repositioning Meets Precision in Glioblastoma.
Wick W, Kessler T. Wick W, et al. Among authors: kessler t. Clin Cancer Res. 2018 Jan 15;24(2):256-258. doi: 10.1158/1078-0432.CCR-17-2989. Epub 2017 Nov 13. Clin Cancer Res. 2018. PMID: 29133572
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
Pfaff E, Kessler T, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW, Wick W, Sahm F. Pfaff E, et al. Among authors: kessler t. Neuro Oncol. 2018 May 18;20(6):826-837. doi: 10.1093/neuonc/nox216. Neuro Oncol. 2018. PMID: 29165638 Free PMC article.
Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients.
Berberich A, Hielscher T, Kickingereder P, Winkler F, Drüschler K, Riedemann L, Arzt M, Kessler T, Platten M, von Deimling A, Wick W, Sahm F, Bendszus M, Wick A. Berberich A, et al. Among authors: kessler t. Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1472-1480. doi: 10.1016/j.ijrobp.2018.07.2004. Epub 2018 Jul 31. Int J Radiat Oncol Biol Phys. 2018. PMID: 30071292
Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.
Berberich A, Kessler T, Thomé CM, Pusch S, Hielscher T, Sahm F, Oezen I, Schmitt LM, Ciprut S, Hucke N, Ruebmann P, Fischer M, Lemke D, Breckwoldt MO, von Deimling A, Bendszus M, Platten M, Wick W. Berberich A, et al. Among authors: kessler t. Clin Cancer Res. 2019 Jan 1;25(1):253-265. doi: 10.1158/1078-0432.CCR-18-1580. Epub 2018 Oct 1. Clin Cancer Res. 2019. PMID: 30274984
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M. Wick W, et al. Among authors: kessler t. Neuro Oncol. 2019 Jan 1;21(1):95-105. doi: 10.1093/neuonc/noy161. Neuro Oncol. 2019. PMID: 30277538 Free PMC article. Clinical Trial.
719 results